PepTivator® CEF MHC Class I Plus

PepTivator
®
CEF MHC Class 1 Plus consists of 32 MHC-1– specific peptides of 8–12 aa in length. These sequences were derived from cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and influenza virus and have been shown to elicit interferon-gamma release from CD8
+
T cells in most of all individuals
1,2
.
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Data and images for
PepTivator
®
CEF MHC Class I Plus

Figures

Figure 1

View details
Sequences and HLA restrictions of peptides of the PepTivator CEF MHC Class I Plus peptide pool.HLA-allele data according to www.iedb.org.

Figure 1

Sequences and HLA restrictions of peptides of the PepTivator CEF MHC Class I Plus peptide pool.HLA-allele data according to www.iedb.org.

Specifications for
PepTivator
®
CEF MHC Class I Plus

Overview

PepTivator
®
CEF MHC Class 1 Plus consists of 32 MHC-1– specific peptides of 8–12 aa in length. These sequences were derived from cytomegalovirus (HCMV), Epstein-Barr virus (EBV), and influenza virus and have been shown to elicit interferon-gamma release from CD8
+
T cells in most of all individuals
1,2
.
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Detailed product information

Downstream applications

  • PepTivator CEF MHC Class 1 Plus is recommended as a peptide-specific positve control for the detection of CD8+ T cells in human PBMC. This peptide set is used by the NIH. For more information refer to the NIH AIDS Research and Reference Reagent Program.

References for
PepTivator
®
CEF MHC Class I Plus

Publications

  1. Currier, J. R. et al. (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260(1-2): 157-172
  2. Mwau, M. et al. (2002) Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18(9): 611-618

Related products for
PepTivator
®
CEF MHC Class I Plus

2 products available
 

Rapid Cytokine Inspector (CD8 T Cell) Kit, human

T lymphocytes execute and control immunological reactions with a repertoire of cytokines, cytotoxic ...

 

CD137 MicroBead Kit, human

The CD137 MicroBead Kit was developed for the positive selection of human CD137+ cells from PBMCs. ...

Seems like you are coming from USA!
Do you want to visit our website in your country?

Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.